Home   >  
MAPK Pathway

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Exarafenib Chemical Structure
BCP49200 Exarafenib 2639957-39-2
Exarafenib is an antineoplastic. Exarafenib has anticancer activity by suppression of downstream MAPK pathway signaling.
Vemurafenib-Analog Chemical Structure
BCP27823 Vemurafenib-Analog 918505-61-0
Vemurafenib-Analog is a potent BRAF inhibitor and the isomer of Vemurafenib.
KG5 Chemical Structure
BCP46930 KG5 877874-85-6
KG 5 is an orally available PDGFRß and B-Raf allosteric inhibitor.
Encorafenib Chemical Structure
BCP44104 Encorafenib 1269440-29-0
Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Rineterkib hydrochloride Chemical Structure
BCP43938 Rineterkib hydrochloride 1715025-34-5
Rineterkib is a RAF and ERK1/2 inhibitor which has demonstrated preclinical activity in multiple MAPK activated cancer cells and xenograft models.
MCP110 Chemical Structure
BCP43521 MCP110 521310-51-0
MCP110 is an inhibitor of Ras.
Vemurafenib Chemical Structure
BCP43160 Vemurafenib 1029872-54-5
Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.
Lifirafenib Chemical Structure
BCP42783 Lifirafenib 1446090-79-4
Lifirafenib is a Novel potent and selective RAF Kinase and EGFR inhibitor.
Rineterkib Chemical Structure
BCP38204 Rineterkib 1715025-32-3
Rineterkib is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.
Donafenib Chemical Structure
BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
123下一页末页共 51 条记录 1 / 6 页